Advertisement
Screener

Zoetis Inc. (ZTS) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Zoetis Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Zoetis Inc. return tang equity for the quarter ending 2026-06-30 was -800.00%, a 576.42% decline year-over-year.
  • Zoetis Inc. return tang equity for the quarter ending 2026-03-31 was -914.14%, a 567.90% decline year-over-year.
  • Zoetis Inc. return tang equity for the quarter ending 2025-12-31 was -1894.29%, a 1015.90% decline year-over-year.
  • Zoetis Inc. return tang equity for the quarter ending 2025-09-30 was 145.30%, a 9.23% decline year-over-year.
  • Zoetis Inc. return tang equity for fiscal 2025 was -1215.00%, a 651.30% decline from fiscal 2024.
  • Zoetis Inc. return tang equity for fiscal 2024 was 220.39%, a 6.25% increase from fiscal 2023.
  • Zoetis Inc. return tang equity for fiscal 2023 was 207.43%, a 55.65% decline from fiscal 2022.
  • Zoetis Inc. return tang equity for fiscal 2022 was 467.70%, a 31.79% increase from fiscal 2021.
Available history
2011-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-800.00%$2.62B-$327M
2026-03-31-914.14%$2.65B-$290M
2025-12-31-1894.29%$2.65B-$140M
2025-09-30145.30%$2.63B$1.81B
2025-06-30167.92%$2.59B$1.54B
2025-03-31195.37%$2.49B$1.27B
2024-12-31206.82%$2.49B$1.2B
2024-09-30160.08%$2.43B$1.52B
2024-06-30193.72%$2.34B$1.21B
2024-03-31193.76%$2.39B$1.23B
2023-12-31207.43%$2.34B$1.13B
2023-09-30197.57%$2.28B$1.15B
2023-06-30290.42%$2.21B$762M
2023-03-31337.30%$2.07B$614M
2022-12-31467.70%$2.11B$452M
2022-09-30250.55%$2.07B$825M
2022-06-30324.03%$2.09B$645M
2022-03-31290.34%$2.07B$714M
2021-12-31354.88%$2.04B$574M
2021-09-30327.60%$1.98B$605M
2021-06-30989.12%$1.91B$193M
2021-03-31-2039.08%$1.77B-$87M
2020-12-31-379.17%$1.64B-$432M
2020-09-30-244.92%$1.66B-$679M
2020-06-30-131.78%$1.62B-$1.23B
2020-03-31-110.42%$1.61B-$1.46B
2019-12-31-96.28%$1.5B-$1.56B
2019-09-30-91.83%$1.46B-$1.59B
2019-06-30-78.48%$1.38B-$1.75B
2019-03-31-73.56%$1.39B-$1.89B
2018-12-31-68.92%$1.43B-$2.07B
2018-09-30-52.69%$1.16B-$2.21B
2018-06-30-264.22%$1.12B-$422M
2018-03-31-197.98%$978M-$494M
2017-12-31-131.51%$864M-$657M
2017-10-01-192.40%$937M-$487M
2017-07-02-123.66%$878M-$710M
2017-04-02-100.71%$855M-$849M
2016-12-31-91.73%$821M-$895M
2016-10-02-80.40%$689M-$857M
2016-07-03-59.89%$639M-$1.07B
2016-04-03-30.66%$378M-$1.23B
2015-12-31-25.96%$339M-$1.31B
2015-09-27-95.06%$443M-$466M
2015-06-28-77.78%$420M-$540M
2015-03-29-124.58%$593M-$476M
2014-12-31-232.27%$583M-$251M
2014-09-28-241.20%$562M-$233M
2014-06-29-145.98%$527M-$361M
2014-03-30-93.35%$519M-$556M
2013-12-31-71.49%$504M-$705M
2013-09-29-48.08%$389M-$809M
2013-06-30-48.17%$420M-$872M
2013-03-31-46.73%$465M-$995M
2012-12-3118.84%$436M$2.31B

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-1215.00%$2.67B-$220M
2024-12-31220.39%$2.49B$1.13B
2023-12-31207.43%$2.34B$1.13B
2022-12-31467.70%$2.11B$452M
2021-12-31354.88%$2.04B$574M
2020-12-31-379.17%$1.64B-$432M
2019-12-31-96.28%$1.5B-$1.56B
2018-12-31-68.92%$1.43B-$2.07B
2017-12-31-131.51%$864M-$657M
2016-12-31-91.73%$821M-$895M
2015-12-31-25.96%$339M-$1.31B
2014-12-31-232.27%$583M-$251M
2013-12-31-71.49%$504M-$705M
2012-12-3118.84%$436M$2.31B
2011-12-318.92%$245M$2.75B

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10